LB PHARMACEUTICALS INC (LBRX)
$47.75-$0.16 (-0.33%) Today
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 286,205 | $10.00M |
| Grant or award | 7 | 72,500 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
26 Form 4 filings on record, the earliest from Sep 10, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. - 10% Owner | Open-market purchase | Pre-Funded Warrants (Right to Buy) | 286,205 | $34.94 | $10.00M | |
 Robert R. Ruffolo | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Ran Nussbaum | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Rebecca Luse | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Robert A. Lenz | Grant or award | Stock Option (Right to Buy) | 12,500 | $0.00 | - | |
| Rekha Hemrajani | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| William P. Kane Jr. | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| J. Scott Garland | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Robert A. Lenz | Grant or award | Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
| Deep Track Biotechnology Master Fund, Ltd. | Open-market purchase | Pre-Funded Warrants (Right to Buy) | 378,444 | $21.17 | $8.01M | |
| Deep Track Biotechnology Master Fund, Ltd. | Open-market purchase | Pre-Funded Warrants (Right to Buy) | 93,925 | $21.17 | $1.99M | |
| Deep Track Biotechnology Master Fund, Ltd. | Other | Common Stock | 686,138 | - | - | |
| Deep Track Biotechnology Master Fund, Ltd. | Open-market purchase | Common Stock | 2,000,000 | $15.00 | $30.00M | |
| Deep Track Biotechnology Master Fund, Ltd. | Open-market purchase | Common Stock | 666,666 | $15.00 | $10.00M | |
| Deep Track Biotechnology Master Fund, Ltd. | Other | Series C Preferred Stock | 16,666,667 | - | - | |
| Pontifax Management 4 G.P. (2015) Ltd. | Other | Common Stock | 411,681 | - | - | |
| Pontifax Management 4 G.P. (2015) Ltd. | Open-market purchase | Common Stock | 1,000,000 | $15.00 | $15.00M | |
| Pontifax Management 4 G.P. (2015) Ltd. | Other | Series C Preferred Stock | 10,000,000 | - | - | |
| Ran Nussbaum | Other | Common Stock | 411,681 | - | - | |
| Ran Nussbaum | Open-market purchase | Common Stock | 1,000,000 | $15.00 | $15.00M | |
| Ran Nussbaum | Other | Series C Preferred Stock | 10,000,000 | - | - | |
| Vida Ventures GP III, L.L.C. | Other | Common Stock | 547,648 | - | - | |
| Vida Ventures GP III, L.L.C. | Other | Common Stock | 1,262 | - | - | |
| Vida Ventures GP III, L.L.C. | Open-market purchase | Common Stock | 332,566 | $15.00 | $4.99M | |
| Vida Ventures GP III, L.L.C. | Open-market purchase | Common Stock | 767 | $15.00 | $12K | |
| Vida Ventures GP III, L.L.C. | Other | Series C Preferred Stock | 13,302,666 | $0.00 | - | |
| Vida Ventures GP III, L.L.C. | Other | Series C Preferred Stock | 30,667 | $0.00 | - | |
| Richard Anthony Silva - Officer | Derivative | Employee Stock Option (Right to Buy) | 8,964 | - | - | |
| Richard Anthony Silva - Officer | Grant or award | Employee Stock Option (Right to Buy) | 8,964 | - | - | |
| Richard Anthony Silva - Officer | Grant or award | Employee Stock Option (Right to Buy) | 80,899 | $0.00 | - | |
| Robert R. Ruffolo | Derivative | Stock Option (Right to Buy) | 1,792 | - | - | |
| Robert R. Ruffolo | Grant or award | Stock Option (Right to Buy) | 1,792 | - | - | |
| Robert R. Ruffolo | Derivative | Stock Option (Right to Buy) | 717 | - | - | |
| Robert R. Ruffolo | Grant or award | Stock Option (Right to Buy) | 717 | - | - | |
| Robert R. Ruffolo | Derivative | Stock Option (Right to Buy) | 10,757 | - | - | |
| Robert R. Ruffolo | Grant or award | Stock Option (Right to Buy) | 10,757 | - | - | |
| Robert R. Ruffolo | Grant or award | Stock Option (Right to Buy) | 22,449 | $0.00 | - | |
| Ran Nussbaum | Grant or award | Stock Option (Right to Buy) | 22,449 | $0.00 | - | |
| J. Scott Garland | Derivative | Employee Stock Option (Right to Buy) | 17,929 | - | - | |
| J. Scott Garland | Grant or award | Employee Stock Option (Right to Buy) | 17,929 | - | - | |
| J. Scott Garland | Derivative | Employee Stock Option (Right to Buy) | 3,585 | - | - | |
| J. Scott Garland | Grant or award | Employee Stock Option (Right to Buy) | 3,585 | - | - | |
| J. Scott Garland | Grant or award | Employee Stock Option (Right to Buy) | 22,449 | $0.00 | - | |
| Rebecca Luse | Grant or award | Stock Option (Right to Buy) | 22,449 | $0.00 | - | |
| Rekha Hemrajani | Grant or award | Stock Option (Right to Buy) | 22,449 | $0.00 | - | |
| William P. Kane Jr. | Grant or award | Stock Option (Right to Buy) | 22,449 | $0.00 | - | |
 Heather D. Turner - Officer | Derivative | Employee Stock Option (Right to Buy) | 175,706 | - | - | |
| Heather D. Turner - Officer | Grant or award | Employee Stock Option (Right to Buy) | 175,706 | - | - | |
| Heather D. Turner - Officer | Derivative | Employee Stock Option (Right to Buy) | 7,857 | - | - | |
| Heather D. Turner - Officer | Grant or award | Employee Stock Option (Right to Buy) | 7,857 | - | - | |
| Heather D. Turner - Officer | Grant or award | Employee Stock Option (Right to Buy) | 971,828 | $0.00 | - | |
 Marc L. Panoff - Officer | Derivative | Employee Stock Option (Right to Buy) | 3,944 | - | - | |
| Marc L. Panoff - Officer | Grant or award | Employee Stock Option (Right to Buy) | 3,944 | - | - | |
| Marc L. Panoff - Officer | Derivative | Employee Stock Option (Right to Buy) | 896 | - | - | |
| Marc L. Panoff - Officer | Grant or award | Employee Stock Option (Right to Buy) | 896 | - | - | |
| Marc L. Panoff - Officer | Derivative | Employee Stock Option (Right to Buy) | 1,255 | - | - | |
| Marc L. Panoff - Officer | Grant or award | Employee Stock Option (Right to Buy) | 1,255 | - | - | |
| Marc L. Panoff - Officer | Derivative | Employee Stock Option (Right to Buy) | 14,343 | - | - | |
| Marc L. Panoff - Officer | Grant or award | Employee Stock Option (Right to Buy) | 14,343 | - | - | |
| Marc L. Panoff - Officer | Derivative | Employee Stock Option (Right to Buy) | 7,171 | - | - | |
| Marc L. Panoff - Officer | Grant or award | Employee Stock Option (Right to Buy) | 7,171 | - | - | |
| Marc L. Panoff - Officer | Grant or award | Employee Stock Option (Right to Buy) | 90,525 | $0.00 | - | |
| Gad Soffer - Officer | Derivative | Employee Stock Option (Right to Buy) | 26,893 | - | - | |
| Gad Soffer - Officer | Grant or award | Employee Stock Option (Right to Buy) | 26,893 | - | - | |
| Gad Soffer - Officer | Grant or award | Employee Stock Option (Right to Buy) | 229,860 | $0.00 | - | |
| Anna Eramo - Officer | Derivative | Employee Stock Option (Right to Buy) | 26,893 | - | - | |
| Anna Eramo - Officer | Grant or award | Employee Stock Option (Right to Buy) | 26,893 | - | - | |
| Anna Eramo - Officer | Derivative | Employee Stock Option (Right to Buy) | 6,275 | - | - | |
| Anna Eramo - Officer | Grant or award | Employee Stock Option (Right to Buy) | 6,275 | - | - | |
| Anna Eramo - Officer | Grant or award | Employee Stock Option (Right to Buy) | 155,812 | $0.00 | - | |
 Zachary Prensky | Derivative | Stock Option (Right to Buy) | 3,944 | - | - | |
| Zachary Prensky | Grant or award | Stock Option (Right to Buy) | 3,944 | - | - | |
| Zachary Prensky | Derivative | Stock Option (Right to Buy) | 896 | - | - | |
| Zachary Prensky | Grant or award | Stock Option (Right to Buy) | 896 | - | - | |
| Zachary Prensky | Derivative | Stock Option (Right to Buy) | 1,255 | - | - | |
| Zachary Prensky | Grant or award | Stock Option (Right to Buy) | 1,255 | - | - | |
| Zachary Prensky | Derivative | Stock Option (Right to Buy) | 17,929 | - | - | |
| Zachary Prensky | Grant or award | Stock Option (Right to Buy) | 17,929 | - | - | |
| Zachary Prensky | Derivative | Stock Option (Right to Buy) | 53,787 | - | - | |
| Zachary Prensky | Grant or award | Stock Option (Right to Buy) | 53,787 | - | - | |
| Zachary Prensky | Grant or award | Stock Option (Right to Buy) | 22,449 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
LB PHARMACEUTICALS INC (LBRX) had 8 insider filings in the last 90 days, with the most recent on 2026-08-03. The full record for LBRX runs to 26 Form 4 filings, the earliest from 2025-09-10. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
1 insider purchase of LBRX was filed in the last 90 days, totaling $10.00M.
No insider sales of LBRX were filed in the last 90 days.
This page tracks LBRX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add LBRX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
